Výsledky vyhledávání - "Robert F. Marschke"

The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma

Autor: Robert F. Marschke, William L. McGinnis, Rajender K. Ahuja, Edward G. Shaw, Edward T. Creagan, Patricia A. Johnson, Phillip J. Stella, James A. Mailliard, Jeff A. Sloan, James A. Bonner

Publikováno v: Cancer. 82:1037-1048

BACKGROUND A three-arm Phase III randomized trial was performed to compare response rates, time to local or distant progression, and survival for patients with unresectable (Stage IIIA or IIIB) nonsmall cell lung carcinoma treated with standard fract

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7f17efb7476c44c5e17aa5680ce234d4
https://doi.org/10.1002/(sici)1097-0142(19980315)82:6<1037::aid-cncr5>3.0.co

Zobrazit plný text záznamu

Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma

Autor: Henry D. Tazelaar, Jeffrey T. Schleusener, Jeffrey L. Myers, Richard M. Goldberg, Peter J. Cera, Sin-Ho Jung, Stephen S. Cha, Robert F. Marschke, Edward T. Creagan

Publikováno v: Cancer. 77:1284-1291

BACKGROUND Neuroendocrine differentiation can be identified in 10–30% of patients with nonsmall cell lung carcinoma (NSCLC) by immunohistochemical or electron microscopic techniques. However, its clinical significance is not well established. METHO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9d6dcc32a63f09f17877f3dbc646e0ba
https://doi.org/10.1002/(sici)1097-0142(19960401)77:7<1284::aid-cncr9>3.0.co

Zobrazit plný text záznamu

Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial

Autor: Georgene Schroeder, Thomas E. Witzig, Robert F. Marschke, Harold E. Windschitl, James B. Gerstner, James A. Mailliard, Gerardo Colon-Otero, Louis Letendre

Publikováno v: Journal of Clinical Oncology. 13:2012-2015

PURPOSE Malignant cells from non-Hodgkin's lymphomas (NHL) have been shown to express the somatostatin receptor on their cell surface and most NHL are visible on somatostatin radioscintigraphy scans. This provided the rationale to conduct a phase II

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b9112ae310010ba062b2463bd875cf
https://doi.org/10.1200/jco.1995.13.8.2012

Zobrazit plný text záznamu

Prospective phase I evaluation of radiation therapy, 5-fluorouracil, and levamisole in locally advanced gastrointestinal cancer

Autor: Allan J. Schutt, Robert F. Marschke, James A. Martenson, Gordon L. Grado, William J. Maples

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 28:439-443

Purpose: A recent clinical trial in patients with resected node-positive colon cancer demonstrated a clear survival advantage for patients treated with adjuvant 5-fluorouracil and levamisole. This finding led to interest in development of a Phase III

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7ce7e51826a8ae4fa7bf8deb1777013
https://doi.org/10.1016/0360-3016(94)90068-x

Zobrazit plný text záznamu

A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma

Autor: Robert J. Dalton, Henry D. Tazelaar, Geof A. Witrak, James A. Mailliard, Paul S. Etzell, Larry P. Ebbert, James R. Jett, John F. Foley, John Q. Su, Andrew W. Maksymiuk, Robert F. Marschke, Carl G. Kardinal, Michael H. Veeder

Publikováno v: Cancer. 70:2281-2287

BACKGROUND In an effort to confirm the efficacy of mitomycin C against metastatic squamous cell lung carcinoma and to compare the efficacy of single-agent therapy with a combination containing cisplatin, the authors conducted a randomized Phase III t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5207549de2a61607e5b9549ef7362fd6
https://doi.org/10.1002/1097-0142(19921101)70:9<2281::aid-cncr2820700912>3.0.co

Zobrazit plný text záznamu

Phase II Study of High-Dose Somatostatin Analogue in Patients Either Previously Treated or Untreated Who Have Extensive-Stage Small Cell Lung Cancer

Autor: Robert F. Marschke, James B. Gerstner, Donald B. Wender, James A. Mailliard, Roscoe F. Morton, Chirantan Ghosh, James R. Jett, Ralph Levitt, Joseph P. Grill, Jeff A. Sloan

Publikováno v: American Journal of Clinical Oncology. 22:15-17

The authors conducted a phase II study of somatostatin analogue in 18 patients with extensive stage small cell lung cancer (four with previous treatment, 14 without previous treatment). Patients received 2,000 mg subcutaneously thrice daily. They wer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f409aeaabaad4450f87bd98ac11c3bdc
https://doi.org/10.1097/00000421-199902000-00004

Zobrazit plný text záznamu

Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group

Autor: S F Brunk, Robert F. Marschke, Michael H. Veeder, James A. Mailliard, L K Everson, D I Twito, James R. Jett, Robert J. Dalton, James E. Krook, Terry M. Therneau

Publikováno v: Journal of Clinical Oncology. 8:33-38

In this randomized study involving patients with limited-stage small-cell lung cancer (LD-SCC), we compared treatment with either cyclophosphamide; doxorubicin, and vincristine (CAV) or CAV plus etoposide (CAVE). All patients received identical thora

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02596f3ae90cb761bde9c8de44261f52
https://doi.org/10.1200/jco.1990.8.1.33

Zobrazit plný text záznamu

Combined Levamisole With Recombinant Interleukin-2 (IL-2) in Patients With Advanced Renal Cell Carcinoma

Autor: Suresh G. Nair Md, James E. Krook, Robert D. Hestorff, Vera J. Suman, John C. Michalak, Edward T. Creagan, Robert F. Marschke, Loren K. Tschetter, John W. Kugler, James A. Mailliard

Publikováno v: American Journal of Clinical Oncology. 21:139-141

Adoptive immunotherapy (AI) with interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells is an antineoplastic modality in which immune-activated cells are administered to a host having cancer in an attempt to mediate tumor regression. Levami

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ea1883d9c817077aab341b34f27c2c
https://doi.org/10.1097/00000421-199804000-00008

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání